GPI-1485 Guilford

Marshall, V.L. and Grosset, D.G. (2004) GPI-1485 Guilford. Current Opinion in Investigational Drugs, 5(1), pp. 107-112. (PMID:14983983)

Full text not currently available from Enlighten.


GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Grosset, Dr Donald
Authors: Marshall, V.L., and Grosset, D.G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Neuroscience and Psychology
Journal Name:Current Opinion in Investigational Drugs
Publisher:Pharma Press Ltd
ISSN (Online):2040-3429

University Staff: Request a correction | Enlighten Editors: Update this record